Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

Jim Cramer, the host of Mad Money, recently revisited one of his core investment principles: "Nobody ever made a dime ...

Hunter Associates Investment Management LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 23.6% in the fourth quarter, according to the company in its most recent filing with the ...

Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

REUTERS/Brendan McDermid/File Photo U.S. stocks ended lower on Friday, with indexes losing ground after the White House said U.S. President Donald Trump will implement on Saturday tariffs of 25% ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

Nasdaq Data Link is a marketplace for financial, economic and alternative data delivered in modern formats for today's analysts, including Python, Excel.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...